The Government welcomes the Committee’s recognition that the UK is world-leading in genomic testing. The Government will continue to support the UK’s genomic testing industry and recognises that it plays an important role in the UK’s thriving life sciences sector, bringing benefits for the population’s health and the economy. In July 2021, the Government launched its Life Sciences Vision,3 which was commissioned by the Prime Minister to outline the Government’s and the life sciences sector’s ambitions over the next decade. This vision demonstrates the Government’s commitment to growing the UK’s life sciences sector, including the DTC genomic testing industry. Furthermore, through its publication of Genome UK last year, and its subsequent Implementation Plan,4 the Government demonstrated a commitment to supporting the development of genomic technologies in an environment that promotes responsible, equitable and ethical patient care. Implementation of Genome UK is supported by a robust governance system. This includes the Minister-chaired National Genomics Board, providing strategic oversight, as well as an Implementation Coordination Group (ICG) which monitors the delivery of Genome UK’s commitments more closely. These groups bring delivery partners and stakeholders together, with UK-wide representation. Progress against the delivery of Genome UK’s commitments has been made possible thanks to consistent government investment in Genomics England, the NHS Genomic Medicine Service, and the UK’s valuable research programmes, such as UK Biobank and Our Future Health. As part of the first Implementation Plan for Genome UK, the Government announced the roll-out of a world-first whole genome sequencing (WGS) programme to patients with a suspected rare disease and certain cancers in the NHS Genomic Medicine Service, in partnership with Genomics England. More broadly, the NHS continues to develop innovative testing strategies for the early detection of cancer and hereditary diabetes and high cholesterol, such as through the commercial agreement with the diagnostic company GRAIL announced in November 2020. Furthermore, Our Future Health (formerly known as the Accelerating Detection of Disease challenge) is helping to drive developments in the next generation of diagnostics and clinical tools, including the evaluation of polygenic risk scores (PRS). This ground- breaking research programme, supported by Government investment, will further enhance the genomic testing industry in the UK, whilst of course bringing health benefits to the UK’s population. We would like to thank the Committee for supporting the policies that have enabled the UK to become a world leader in genomics and life sciences.